Creating safer and longer-lasting mRNA therapies using engineered bacteria
Engineering bacterial group I introns for efficient production of safe and durable nucleoside-modified circular mRNA therapeutics
This study is looking at new ways to create safer and more effective mRNA treatments for various diseases, which could lead to therapies that last longer in your body and have fewer side effects.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-11070783 on NIH RePORTER |
What this research studies
This research focuses on developing new methods to produce circular messenger RNAs (mRNAs) that are modified to be safer and more effective as therapeutics. By using a specific bacterial intron from Azoarcus, the team aims to enhance the stability and longevity of these mRNAs, which are crucial for treating various diseases. The study will explore how certain chemical modifications to the mRNA affect its ability to be circularized, which is essential for its therapeutic efficacy. Patients may benefit from improved mRNA therapies that have fewer side effects and longer-lasting effects in the body.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that could be treated with mRNA therapeutics, such as genetic disorders or certain cancers.
Not a fit: Patients who do not have conditions that can be addressed by mRNA therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer mRNA-based treatments for a variety of diseases.
How similar studies have performed: Previous research has shown promise in using modified mRNAs for therapeutic purposes, but this specific approach using engineered bacterial introns is relatively novel.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Felix Mejia, Alejandro — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Felix Mejia, Alejandro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.